Supersalud demands that EPS solve delays in delivery of medicines
The National Health Superintendency (Supersalud), led by Giovanny Rubiano García, demanded that Health Promoting Entities (EPS), both intervened and non-intervened, expedite the implementation of measures that ensure the complete and timely delivery of medicines to patients with special health conditions.
"In the total number of claims for undelivered, untimely or incomplete health technologies, 5 EPSs, including those that were intervened and those that were not intervened, account for 68.16 percent of the total claims for this cause ," the entity indicated.
According to the official statement, there are 217,108 complaints concentrated in five EPS: Nueva EPS, Salud Total, Sanitas, EPS Sura and Coosalud ,
Nueva EPS leads the claims for delays in the delivery of these technologies and has presented the monthly and annual costs by cohort.
Giovanny Rubiano García demanded that the EPS, under intervention and not intervened, advance in solutions for the delivery of medicines to patients with special health conditions. In the total of claims for health technologies not delivered, untimely or incomplete, 5 EPS… pic.twitter.com/yj0UifIaxN
— Supersalud (@Supersalud) February 25, 2025
The intervening agent, Bernardo Camacho, said that when he assumed his role he found outstanding debts with pharmaceutical managers and exclusivity problems in certain molecules to treat orphan diseases, a situation that has already been resolved.
"The auditor explained that the EPS must allocate 4 billion pesos per month for transplant patients alone. In the case of cancer treatments, 50 billion pesos per month. In total, the annual cost of medications for high-cost patients and those with chronic non-communicable diseases is more than $1 trillion per year, or $110 billion per month," the entity added.
On the other hand, the Nueva EPS medicines team reported that it held simultaneous talks with pharmaceutical managers and the industry to reach payment agreements that guarantee the complete and timely delivery of the medicines.
Supersalud demands that EPS solve delays in delivery of medicines. Photo: Private archive
"We have a situation in which there is a discrepancy between what is paid to the manager and what he delivers, due to what the industry provides him. Sometimes the payments become payments on previous debts and the manager cannot fulfill the agreed delivery," he said.
He also shared the proposed solutions:
- Segmented dismantling plan that prevents this EPS from depending on a single pharmaceutical manager that dominates the market.
- Payment of advances to some of its suppliers.
- Regularization of payments that had been missed during previous intervention processes.
Supersalud demands that EPS resolve delays in delivery of medicines Photo: iStock
DIGITAL REACH EDITORIAL
eltiempo
